FEATURES >> YouTube | Top acute-care hospitals | Hospital Fires | Top BlackBerry Apps | Commentary
TOPICS >> Stimulus | Health Reform | CMS News | Finance | EMRs | Mobile Healthcare | Hospital Leadership Blog
FDA's medical approval process faces GAO scrutiny
Comments
By Anonymous | Posted 1:02pm | October 27, 2008
yada yada yada.
If we don't have a way to bring devices to the forefront, then no one will take the risk-reward to make it happen. Human nature.
The article is biased against mammosite. It has a good 4 year track record with low failure rates.
Additionally PATIENTS CANNOT ENROLL ON THE B39 TRIAL if they are NODE NEGATIVE. It is CLOSED to them.
These are the patients who are best suited - should we not allow them to get an equivalent treatment at 4 years follow up (actually better than standard tangents) ?
I think not..





